Recent News

• 06.11.2026 - Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
• 05.11.2026 - Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
• 04.29.2026 - Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
• 04.27.2026 - Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
• 04.22.2026 - Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
• 03.24.2026 - Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
• 03.06.2026 - Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Recent Filings

• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.11.2026 - EX-99.1 EX-99.1
• 05.11.2026 - 8-K Current report
• 05.08.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.09.2026 - 8-K Current report
• 04.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.09.2026 - 4 Statement of changes in beneficial ownership of securities